Back to results

A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination

Primary Purpose

Hepatitis C Infection, HIV Infection

Status

Completed

Phase

Phase 1

Locations

United Kingdom

Study Type

Interventional

Intervention

AdCh3NSmut1

MVA-NSmut

ChAdV63.HIVconsv

MVA.HIVconsv

About this trial

This is an interventional prevention trial for Hepatitis C Infection

Eligibility Criteria

18 Years - 50 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

Healthy males or females, as assessed by medical history, physical examination and laboratory tests
Aged at least 18 years on the day of screening and no greater than 50 years on the day of the first vaccination
Resident in or easy access to the trial site for the duration of the study
Available for follow-up for the planned duration of the study
Able and willing (in the Chief Investigator's opinion) to comply with all study requirements
Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner
For females, willingness to practice continuous effective contraception from screening until 4 months after the last immunisation.
All female volunteers must be willing to undergo urine pregnancy tests at the time points specified in the Schedule of Procedures and must have a negative pregnancy test on the day(s) of vaccination
For sexually active men, willingness to use an approved method of contraception until four months after the last vaccination
Agreement to refrain from blood donation during the course of the study
In the opinion of the Chief Investigator or designee, the volunteer has understood the information provided. Written informed consent must be given before any study-related procedures are performed
Willing to undergo HCV/HIV-1 testing, counselling and receive test results

Exclusion Criteria:

Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period
Prior receipt of a recombinant simian adenoviral vaccine
Receipt of any investigational HIV-1 or HCV vaccine within the last 6 years
Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate
Receipt of live attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with the IMP
Receipt of other vaccine, including influenza vaccine, within the previous 14 days or planned receipt within 14 days after vaccination with the IMP
Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressive medication within the past 6 months (inhaled and topical steroids are allowed)
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine
History of clinically significant contact dermatitis
Any history of anaphylaxis in reaction to vaccination
Pregnancy, lactation or intention to become pregnant during the study
History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
History of serious psychiatric condition
Any other serious chronic illness requiring hospital specialist supervision
Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week
Suspected or known injecting drug use
Reported high-risk behaviour for HIV-1 / HCV infection
Seropositive for hepatitis B surface antigen (HBsAg)
Seropositive for HIV-1 (antibodies to HIV-1) at screening
Seropositive for hepatitis C virus (antibodies to HCV) at screening
Any other clinically significant acute or chronic medical condition that is considered unstable/progressive, or in the opinion of the Chief Investigator, may either put the volunteer at risk because of participation in the study, or may influence the result of the study, or the volunteer's ability to participate in the study
Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis
Any other finding which in the opinion of the investigators would significantly increase the risk of having an adverse outcome from participating in the protocol
Vulnerable subjects (according to ICH GCP)

Sites / Locations

Centre for Clinical Vaccinology and Tropical Medicine

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Arm Label

Group 1

Group 2

Group 3

Arm Description

Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8. Subjects: 8 healthy volunteers.

Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10^8 pfu at week 8. Subjects: 8 healthy volunteers.

Interventions: AdCh3NSmut1, MVA-NSmut, ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp and 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0, and 1 dose MVA-NSmut 1 x 10^8 pfu and 1 dose MVA.HIVconsv 1 x 10^8 pfu at week 8. Subjects: 16 healthy volunteers.

Outcomes

Primary Outcome Measures

Safety of administering simultaneous HCV/HIV-1 prime-boost vaccinations, as measured by the proportion of volunteers who develop a grade 3 or 4 local or systemic reaction

Proportion of volunteers who develop a grade 3 or 4 local reaction Proportion of volunteers who develop a grade 3 or 4 systemic reaction

Secondary Outcome Measures

Cellular immune response generated by simultaneous HCV/HIV-1 prime-boost vaccinations, as determined by analysing changes in the magnitude or quality of HCV and HIV-1-specific cellular immune responses.

Immunogenicity determined by analysing changes from baseline in the magnitude or quality of HCV and HIV-1-specific cellular immune responses. These will be detected using several standardised assays. The primary outcome measure for immunogenicity will be the development of T cell responses to HCV and HIV-1 epitopes, as determined by IFN-ɣ ELISpot assay. In addition, several exploratory immunology assays (including but not limited to intracellular cytokine staining, phenotype, viral suppression in vitro) will be developed and used.

Full Information

NCT ID

NCT02362217

First Posted

November 6, 2014

Last Updated

October 10, 2018

Sponsor

University of Oxford

Collaborators

ReiThera Srl, GlaxoSmithKline

1. Study Identification

Unique Protocol Identification Number

NCT02362217

Brief Title

A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination

Official Title

A Phase I Study to Evaluate the Safety and Immunogenicity of Simultaneous Prime-Boost Immunisations With Candidate HCV and HIV-1 Vaccines, AdCh3NSmut1 / ChAdV63.HIVconsv and MVA-NSmut / MVA.HIVconsv, in Healthy Volunteers

Study Type

Interventional

2. Study Status

Record Verification Date

October 2018

Overall Recruitment Status

Completed

Study Start Date

October 2014 (Actual)

Primary Completion Date

August 2016 (Actual)

Study Completion Date

October 31, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

University of Oxford

Collaborators

ReiThera Srl, GlaxoSmithKline

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

This study is aimed at assessing the safety of candidate Hepatitis C vaccines AdCh3NSmut/MVA-NSmut and HIV vaccines ChAdV63.HIVconsv/MVA.HIVconsv when administered separately or in combination to healthy volunteers. The study also aims to assess the cellular immune response generated by these vaccines when administered as mentioned above.

Detailed Description

Hepatitis C and HIV are both widespread pathogens. By the end of 2010, there were 2.3 million people in Europe living with HIV, over half of whom were coinfected with the Hepatitis C virus (HCV). Although vaccination is the optimal method of preventing infection, it has proved extremely difficult to develop an effective vaccine against HIV and HCV due to the enormous variation in strains around the world. This is caused by the extraordinary ability of the viruses to change their genetic material. Researchers at the University of Oxford have developed novel candidate vaccines against HIV ('HIV.consv') and HCV ('NSmut'). These vaccines have been inserted into the carrier viruses Chimpanzee Adenovirus (ChAd or AdCh) and modified vaccinia virus Ankara (MVA), both of which have excellent safety records. The aim of this study is to test for the first time the response of the immune system when vaccines to both HIV and HCV are given together. During this study, 32 healthy adults aged 18 to 50 years will be recruited into one of three groups to receive either two or four intramuscular injections over a period of two months. All participants will be followed up for a further six months (12 visits in total).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Hepatitis C Infection, HIV Infection

7. Study Design

Primary Purpose

Prevention

Study Phase

Phase 1

Interventional Study Model

Parallel Assignment

Masking

None (Open Label)

Allocation

Non-Randomized

Enrollment

33 (Actual)

8. Arms, Groups, and Interventions

Arm Title

Group 1

Arm Type

Experimental

Arm Description

Interventions: AdCh3NSmut1, MVA-NSmut. Administration schedule: 1 dose AdCh3NSmut1 2.5 x 10^10 vp at week 0 and 1 dose MVA-NSmut 2 x 10^8 pfu at week 8. Subjects: 8 healthy volunteers.

Arm Title

Group 2

Arm Type

Experimental

Arm Description

Interventions: ChAdV63.HIVconsv, MVA.HIVconsv. Administration schedule: 1 dose ChAdV63.HIVconsv 5 x 10^10 vp at week 0 and 1 dose MVA.HIVconsv 2 x 10^8 pfu at week 8. Subjects: 8 healthy volunteers.

Arm Title

Group 3

Arm Type

Experimental

Arm Description

Intervention Type

Biological

Intervention Name(s)

AdCh3NSmut1

Intervention Description

Genetic vaccine against Hepatitis C virus infection

Intervention Type

Biological

Intervention Name(s)

MVA-NSmut

Intervention Description

Genetic vaccine against Hepatitis C virus infection

Intervention Type

Biological

Intervention Name(s)

ChAdV63.HIVconsv

Intervention Description

Genetic vaccine against HIV-1 infection

Intervention Type

Biological

Intervention Name(s)

MVA.HIVconsv

Intervention Description

Genetic vaccine against HIV-1 infection

Primary Outcome Measure Information:

Title

Safety of administering simultaneous HCV/HIV-1 prime-boost vaccinations, as measured by the proportion of volunteers who develop a grade 3 or 4 local or systemic reaction

Description

Proportion of volunteers who develop a grade 3 or 4 local reaction Proportion of volunteers who develop a grade 3 or 4 systemic reaction

Time Frame

Actively collected throughout the study until 6 months after the last vaccination

Secondary Outcome Measure Information:

Title

Description

Time Frame

Actively collected throughout the study until 6 months after the last vaccination

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Maximum Age & Unit of Time

50 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Healthy males or females, as assessed by medical history, physical examination and laboratory tests Aged at least 18 years on the day of screening and no greater than 50 years on the day of the first vaccination Resident in or easy access to the trial site for the duration of the study Available for follow-up for the planned duration of the study Able and willing (in the Chief Investigator's opinion) to comply with all study requirements Willing to allow the investigators to discuss the volunteer's medical history with their General Practitioner For females, willingness to practice continuous effective contraception from screening until 4 months after the last immunisation. All female volunteers must be willing to undergo urine pregnancy tests at the time points specified in the Schedule of Procedures and must have a negative pregnancy test on the day(s) of vaccination For sexually active men, willingness to use an approved method of contraception until four months after the last vaccination Agreement to refrain from blood donation during the course of the study In the opinion of the Chief Investigator or designee, the volunteer has understood the information provided. Written informed consent must be given before any study-related procedures are performed Willing to undergo HCV/HIV-1 testing, counselling and receive test results Exclusion Criteria: Participation in another research study involving an investigational product in the 30 days preceding enrolment, or planned use during the study period Prior receipt of a recombinant simian adenoviral vaccine Receipt of any investigational HIV-1 or HCV vaccine within the last 6 years Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate Receipt of live attenuated vaccine within the previous 60 days or planned receipt within 60 days after vaccination with the IMP Receipt of other vaccine, including influenza vaccine, within the previous 14 days or planned receipt within 14 days after vaccination with the IMP Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections and chronic (more than 14 days) immunosuppressive medication within the past 6 months (inhaled and topical steroids are allowed) History of allergic disease or reactions likely to be exacerbated by any component of the vaccine History of clinically significant contact dermatitis Any history of anaphylaxis in reaction to vaccination Pregnancy, lactation or intention to become pregnant during the study History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ) History of serious psychiatric condition Any other serious chronic illness requiring hospital specialist supervision Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week Suspected or known injecting drug use Reported high-risk behaviour for HIV-1 / HCV infection Seropositive for hepatitis B surface antigen (HBsAg) Seropositive for HIV-1 (antibodies to HIV-1) at screening Seropositive for hepatitis C virus (antibodies to HCV) at screening Any other clinically significant acute or chronic medical condition that is considered unstable/progressive, or in the opinion of the Chief Investigator, may either put the volunteer at risk because of participation in the study, or may influence the result of the study, or the volunteer's ability to participate in the study Any clinically significant abnormal finding on screening biochemistry or haematology blood tests or urinalysis Any other finding which in the opinion of the investigators would significantly increase the risk of having an adverse outcome from participating in the protocol Vulnerable subjects (according to ICH GCP)

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Lucy Dorrell, Prof.

Organizational Affiliation

University of Oxford

Official's Role

Study Chair

First Name & Middle Initial & Last Name & Degree

Ellie Barnes, Prof.

Organizational Affiliation

University of Oxford

Official's Role

Principal Investigator

First Name & Middle Initial & Last Name & Degree

Tomas Hanke, Prof.

Organizational Affiliation

University of Oxford

Official's Role

Principal Investigator

Facility Information:

Facility Name

Centre for Clinical Vaccinology and Tropical Medicine

City

Oxford

State/Province

Oxfordshire

ZIP/Postal Code

OX3 7LE

Country

United Kingdom

12. IPD Sharing Statement

Plan to Share IPD

Undecided

Citations:

PubMed Identifier

30713538

Citation

Hartnell F, Brown A, Capone S, Kopycinski J, Bliss C, Makvandi-Nejad S, Swadling L, Ghaffari E, Cicconi P, Del Sorbo M, Sbrocchi R, Esposito I, Vassilev V, Marriott P, Gardiner CM, Bannan C, Bergin C, Hoffmann M, Turner B, Nicosia A, Folgori A, Hanke T, Barnes E, Dorrell L. A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection. Front Immunol. 2019 Jan 18;9:3175. doi: 10.3389/fimmu.2018.03175. eCollection 2018.

Results Reference

derived

Learn more about this trial

A Study to Assess the Safety of HIV and Hep C Vaccine Candidates When Given Separately or in Combination

We'll reach out to this number within 24 hrs